The Australian government has rejected proposals by the Productivity Commission regarding extending the length of pharmaceutical patents.
Samsung’s biopharmaceutical arm Samsung Bioepis has agreed a deal with Takeda to tackle “unmet disease areas”, marking the South Korean company’s move into the novel drugs market.
China has launched an IP rights protection centre aimed at providing protection for the biopharmaceutical and high-end manufacturing industries.
Takeda has entered into an exclusive licensing agreement with biopharmaceutical company Tesaro to develop a novel cancer therapy in Japan.
Mitsubishi Tanabe has agreed to acquire NeuroDerm, a clinical stage pharmaceutical company, for $1.1 billion.
The creator of OmniRat, the first human monoclonal antibody technology based on rats, outlined the success story of the project yesterday at the 2017 BIO International Convention.
Merck has been granted its first CRISPR technology patent by the Australian Patent Office.
The World Intellectual Property Organization’s Re:Search has launched a new five-year guide to its activities in the fight against neglected tropical diseases, malaria and tuberculosis.
The World Health Organization will launch a pilot project for biosimilars to make costly cancer treatments more widely available in low and middle income countries.
India-based Initiative for Medicines, Access & Knowledge has filed four patent challenges against patents covering hepatitis C drugs in a bid to ensure access to affordable treatment.